Maret G. Traber Professor Emeritus, Linus Pauling Institute, Oregon State University This article is written especially for people who have a genetic defect in the synthesis or secretion of lipoproteins containing apolipoprotein B. These disorders are called abetalipoproteinemia, hypobetalipoproteinemia and related disorders that impair chylomicron formation, such as chylomicron retention disease—all of these disorders are…
Read MoreABL+ Foundation supports individuals with ultra-rare hypolipidemia diseases
Patient Stories
In 1965, the term “rare diseases” was almost unheard of in the United States. Born that year, Paul was diagnosed with Abetalipoproteinemia (ABL), a rare genetic disorder.
“I lead the life I want to live! If you take anything away from my story please realize that ABL, and the other illnesses the ABL+ Foundation is concerned with, are all treatable with proper diet and vitamins.”
Paul’s journey led to the creation of the ABL+ Foundation in 2019.
Hypolipidemia Diseases
On the Blog
α-CEHC – Promising Vitamin E Biomarker Research Presented at NUTRITION 2026
This summer, Yoyo Benchetrit and Dr. Maret Traber presented research at the American Society for Nutrition’s NUTRITION 2026 conference examining α-CEHC, a vitamin E metabolite, as a potential biomarker of vitamin E intake and status. This research may have important future relevance to the ABL community, as lifelong high-dose vitamin E supplementation is a key…
Read More